Press releases

Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron

Important Information on Plaquenil® and COVID-19

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Sanofi completes divestiture of Zentiva to Advent

FDA approves Libtayo as first and only treatment for advanced cutaneous squamous cell carcinoma

Positive Phase 3 results presented for Dupixent show significant improvement on multiple measures of disease sever

Sanofi to refocus two global business units

FDA to review supplemental Biologics License Application for Praluent Injection as potential treatment

Sanofi reaches civil settlement with US SEC

Cablivi approved in Europe for adults with acquired thrombotic thrombocytopenic purpura

Q2 2018 Performance Positions Sanofi for New Growth Phase

Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st

CHMP recommends approval of Cablivi

Sanofi and Advent finalize negotiations for the acquisition of Zentiva

Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

Sanofi successfully prices USD 2 billion bond issue

Sanofi Launches Action 2018, a Worldwide Employee Stock Purchase Plan

New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma

New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent improved moderate-to-severe

Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma